ANKAR

Chr 2

ankyrin and armadillo repeat containing

Predicted to be located in membrane. [provided by Alliance of Genome Resources, Jul 2025]

12
Active trials
28
Pathogenic / LP
276
ClinVar variants
0
Pubs (1 yr)
0.9
Missense Z
1.07
LOEUF
Clinical SummaryANKAR
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
28 Pathogenic / Likely Pathogenic· 220 VUS of 276 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
1.07LOEUF
pLI 0.000
Z-score 1.07
OE 0.85 (0.681.07)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint
0.86Z-score
OE missense 0.91 (0.850.97)
647 obs / 711.2 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.85 (0.681.07)
00.351.4
Missense OE0.91 (0.850.97)
00.61.4
Synonymous OE0.86
01.21.6
LoF obs/exp: 53 / 62.1Missense obs/exp: 647 / 711.2Syn Z: 1.78
GOF
DN
0.5279th %ile
GOF
0.6833th %ile
LOF
0.4825th %ile

The highest-scoring mechanism for this gene is gain-of-function.

GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

276 submitted variants in ClinVar

Classification Summary

Pathogenic27
Likely Pathogenic1
VUS220
Likely Benign15
Benign13
27
Pathogenic
1
Likely Pathogenic
220
VUS
15
Likely Benign
13
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
27
0
27
Likely Pathogenic
0
0
1
0
1
VUS
0
219
1
0
220
Likely Benign
1
9
2
3
15
Benign
0
7
1
5
13
Total1235328276

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

ANKAR · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Systemic SclerosisScleroderma

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

ACTIVE NOT RECRUITING
NCT05925803Phase PHASE3AstraZenecaStarted 2023-11-08
Anifrolumab (blinded)Placebo (blinded)Anifrolumab (unblinded, open label)
Hereditary Autoinflammatory DiseasesSchnitzler SyndromeBehcet Syndrome

AutoInflammatory Disease Alliance Registry (AIDA)

RECRUITING
NCT05200715University of SienaStarted 2020-08-06
No intervention is foreseen by the protocol.
Metastatic Castration-Sensitive Prostate Cancer

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

RECRUITING
NCT06120491Phase PHASE3AstraZenecaStarted 2023-11-21
SaruparibPlaceboAbiraterone Acetate
NSCLC Stage IVPD-L1 Gene MutationAtezolizumab

TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

RECRUITING
NCT07279402Antalya Training and Research HospitalStarted 2025-09-15
Malignant Neoplasm

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

RECRUITING
NCT07252739Phase PHASE2Merck Sharp & Dohme LLCStarted 2025-12-19
MK-1084PembrolizumabCetuximab
Metastatic Castration-sensitive Prostate Cancer

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

ACTIVE NOT RECRUITING
NCT04497844Phase PHASE3Janssen Research & Development, LLCStarted 2020-09-23
NiraparibAbiraterone acetate (AA)Prednisone
Non-small Cell Lung Cancer

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

ACTIVE NOT RECRUITING
NCT03539536Phase PHASE2AbbVieStarted 2018-10-10
Telisotuzumab vedotin
Genetic DiseaseImmune DysfunctionNeurological Diseases or Conditions

Natural History of Type 1 Interferonopathies: Insights From a European Cohort

RECRUITING
NCT07040774Imagine InstituteStarted 2025-10-01
Autism Spectrum Disorder (ASD)

Investigation of the Genetic and Environmental Causes of Autism: a Multi-Center Study

NOT YET RECRUITING
NCT06662591Research and Treatment Society of Genetic DisordersStarted 2025-12-27
Prostate Cancer

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

ACTIVE NOT RECRUITING
NCT04821622Phase PHASE3PfizerStarted 2021-05-12
talazoparib plus enzalutamidePlacebo plus enzalutamide
Acute Coronary Syndrome

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

ACTIVE NOT RECRUITING
NCT05754957Phase PHASE3Janssen Research & Development, LLCStarted 2023-04-07
MilvexianPlacebo
Non-small Cell Lung Cancer

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

RECRUITING
NCT07195695Phase PHASE3Boehringer IngelheimStarted 2026-01-16
ZongertinibPembrolizumabAtezolizumab
Clinical Literature
Landmark / reviewRecent case evidence